Angiotensin-receptor blockers are at least equally effective as angiotensin-converting enzyme inhibitors in reducing mortality in patients with myocardial infarction complicated by left ventricular dysfunction or heart failure [143, 146]. The gene discussed is ACE; the disease is myocardial infarction.